« PreviousJournal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages e55-e79, January 2007
Volume 56, Issue 1 , Pages e55-e79, January 2007
Off-label uses of biologics in dermatology: Rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (Part 2 of 2)
To access this article, please choose from the options below
Funding sources: None.Disclosure: Dr Heffernan has been a paid investigator, lecturer and/or consultant for Abbott, Amgen, Biogen-IDEC, Centocor and Genentech. Drs Heffernan and Graves have been active in industry-sponsored research.Presented at the 63rd Annual Meeting of the American Academy of Dermatology, New Orleans, Louisianna, February 18-22, 2005.
PII: S0190-9622(06)02085-8
doi:10.1016/j.jaad.2006.07.019
© 2007 American Academy of Dermatology, Inc. Published by Elsevier Inc All rights reserved.
« PreviousJournal of the American Academy of Dermatology
Volume 56, Issue 1 , Pages e55-e79, January 2007
Volume 56, Issue 1 , Pages e55-e79, January 2007
